Maximilian Johannes Steinhardt Xiang Zhou Franziska Krummenast Katharina Meckel Katharina Nickel David Böckle Janin Messerschmidt Sebastian Knorz Alexander Dierks Anke Heidemeier Constantin Lapa Hermann Einsele Leo Rasche Klaus Martin Kortüm
10.1177/2058738420980258
Int J Immunopathol Pharmacol
2020 Jan-Dec;34:2058738420980258.
cd38 mor202 daratumumab multiple myeloma refractory relapse
CC BY
https://pubmed.ncbi.nlm.nih.gov/33353443/
ADP-ribosyl Cyclase 1 / antagonists & inhibitors Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Agents, Immunological / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Membrane Glycoproteins / antagonists & inhibitors Multiple Myeloma / drug therapy
ADP-ribosyl Cyclase 1 / antagonists & inhibitors Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Agents, Immunological / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Membrane Glycoproteins / antagonists & inhibitors Multiple Myeloma / drug therapy Case Reports ADP-ribosyl Cyclase 1 / immunology Aged Drug Administration Schedule Drug Resistance, Neoplasm Female Humans Membrane Glycoproteins / immunology Multiple Myeloma / diagnosis Multiple Myeloma / immunology Progression-Free Survival Remission Induction Salvage Therapy Time Factors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Membrane Glycoproteins felzartamab daratumumab CD38 protein, human ADP-ribosyl Cyclase 1
PMC7768838
33353443
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
2020